- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02437136
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer
A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
SNDX-275-0601 is an open-label, Phase 1b/2 study evaluating the combination of entinostat plus pembrolizumab in patients with advanced metastatic or recurrent NSCLC or melanoma or mismatch repair-proficient colorectal cancer. The study has 2 phases, a Dose Escalation/Confirmation Phase (Phase 1b) and an Expansion Phase (Phase 2). An additional cohort (Entinostat Monotherapy Immune Correlate [EMIC] Cohort) evaluating single agent entinostat for 2 weeks followed by the combination will also be evaluated in patients with NSCLC in the Phase 2 expansion phase.
Toxicities will be assessed by the Investigator using the United States (US) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
Dose Confirmation: The prospective MTD/RP2D identified in the Dose Escalation Phase will be confirmed in 9 patients in Dose Confirmation Cohort(s) to obtain additional AE, immune correlate, and anti-tumor activity data on entinostat in combination.
Phase 2 (Expansion): In the Expansion Phase, entinostat in combination will be evaluated using the RP2D identified in the Dose Escalation/Confirmation Phase. Up to 3 Expansion Cohorts consisting of distinct subsets of patients with solid tumor cancers may be explored. Expansion cohorts may include:
- Cohort 1: NSCLC
- Cohort 2: Patients with NSCLC (any histology) who have previously been treated and responded and then progressed on either a PD-1 or PD-L1-blocking antibody
- Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody
- Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody
EMIC Cohort: 15 NSCLC patients Stage 2 of Cohort 1 will be randomly assigned to participate.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Marlene and Stewart Greenbaum Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institution
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- The University of North Carolina at Chapel Hill
-
-
Pennsylvania
-
Easton, Pennsylvania, United States, 18045
- St Luke's University Health Network
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
Nashville, Tennessee, United States, 37230
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with NSCLC:
- Has histologically- or pathologically-confirmed recurrent/metastatic NSCLC.
- If has adenocarcinoma, required to have previously been tested for anaplastic lymphoma kinase (ALK) rearrangements and epidermal growth factor receptor (EGFR) mutations, with results available for collection in this study, and, if positive, has been treated with prior EGFR or ALK therapy.
- Received at least 1 chemotherapeutic regimen in the advanced/metastatic setting and experienced documented, unequivocal progressive disease by either RECIST 1.1 or clinical assessment.
Patients with NSCLC enrolled in Cohort 1 of the Expansion Phase should not have been previously treated with a PD-1/PD-L1-blocking antibody
Patients in Expansion Phase, Cohorts 2 and 3:
Previously treated with a PD-1/PD-L1-blocking antibody and experienced documented, unequivocal radiographic progression of disease by irRECIST, or similar criteria during or within 12 weeks after last dose of such treatment. Patients must have received at least 6 weeks of PD-1/PD-L1 therapy for Cohort 3.
Patients with Melanoma:
In addition to having been previously treated with a PD-1/PD-L1-blocking antibody (inclusion #5), has a histologically- or cytologically-confirmed diagnosis of unresectable or metastatic melanoma and experienced unequivocal progressive disease during treatment with a BRAF inhibitor if BRAF V600 mutation-positive. Treatment with BRAF inhibitor may occur AFTER treatment with the checkpoint inhibitor.
Patients in Expansion Phase, Cohort 4 (Colorectal Cancer):
Received at least 1 chemotherapeutic regimen in the advanced/metastatic setting and experienced documented, unequivocal progressive disease by either RECIST 1.1 or clinical assessment. Must have documented mismatch repair-proficient colon cancer as determined by either immunohistochemistry for mismatch repair proteins or PCR-based functional microsatellite instability. Patients with colorectal cancer enrolled in Cohort 4 should not have been previously treated with a PD-1/PD-L1-blocking antibody (i.e., pembrolizumab, nivolumab, MEDI36MEDI4376, or GNE PDL1 [MPDL3280A])
All Patients:
- Aged 18 years or older on the day written informed consent is given.
- If has brain metastases, must have stable neurologic status following local therapy for at least 4 weeks without the use of steroids or on stable or decreasing dose of ≤10 mg daily prednisone (or equivalent), and must be without neurologic dysfunction that would confound the evaluation of neurologic and other AEs.
Evidence of locally recurrent or metastatic disease based on imaging studies within 28 days before the first study drug dose:
- At least 1 measurable lesion ≥20 mm by conventional techniques or ≥10 mm by spiral CT scan or MRI, with the last imaging performed within 28 days before the first study drug dose. If there is only 1 measurable lesion and it is located in previously irradiated field, it must have demonstrated unequivocal progression according to RECIST, version 1.1.
- If receiving radiation therapy, has a 2-week washout period following completion of the treatment prior to receiving the first study drug dose and continues to have at least 1 measurable lesion, per above criterion.
- ECOG performance status of 0 or 1.
- Has acceptable, applicable laboratory parameters.
- Female subjects must not be pregnant.
- If male, agrees to use an adequate method of contraception
- Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If patient underwent major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
- Willing to have fresh tumor samples collected during screening and at other time points designated as mandatory, per the Schedule of Study Assessments.
- Able to understand and give written informed consent and comply with study procedures.
Exclusion Criteria:
Patients meeting any of the following criteria are not eligible for study participation:
- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
- Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
- History of interstitial lung disease (ILD).
- Allergy to benzamide or inactive components of entinostat.
- History of allergies to any active or inactive ingredients of pembrolizumab or severe hypersensitivity (≥Grade 3) to pembroluzumab.
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator, including, but not limited to:
- Myocardial infarction or arterial thromboembolic events within 6 months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTc interval > 470 msec.
- Uncontrolled heart failure or hypertension, uncontrolled diabetes mellitus, or uncontrolled systemic infection.
- Another known additional malignancy that is progressing or requires active treatment (excluding adequately treated basal cell carcinoma, squamous cell of the skin, cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ, or ductal carinoma in situ of the breast). Prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.
- Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- Active infection requiring systemic therapy.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study drug and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 2 weeks prior to the first dose of study drug or are on stable or decreasing dose of ≤10 mg daily prednisone (or equivalent). This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
- Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- Received a live virus vaccination within 30 days of the first dose of treatment.
- Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to baseline or who has not recovered (i.e., ≤Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier.
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study baseline or who has not recovered (i.e., ≤Grade 1 or at baseline) from AEs due to a previously administered agent.
Note: Patients with ≤Grade 2 neuropathy or ≤Grade 2 alopecia are an exception to this criterion and may qualify for the study.
Note: If patient underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- Received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte-colony stimulating factor [G-CSF], granulocyte macrophage-colony stimulating factor [GM-CSF], or recombinant erythropoietin) within 4 weeks prior to the first dose of study drug.
- Currently receiving treatment with any other agent listed on the prohibited medication list such as valproic acid, or other systemic cancer agents within 14 days of the first dose of treatment.
- If female, is pregnant, breastfeeding, or expecting to conceive, or if male, expect to father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug.
- Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
- Known active hepatitis B (e.g., hepatitis B surface antigen-reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative]).
- For CRC expansion cohort, no prior history of malignant bowel obstruction requiring hospitalization in the 6 months prior to enrollment
- For the CRC expansion cohort, no history of uncontrolled ascites, defined as symptomatic ascites and/or repeated paracenteses for symptom control in the past 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ph 2 NSCLC (squamous or adeno)
Cohort 1: Patients with Non-Small Cell Lung Cancer, with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)
|
An orally available histone deacetylases inhibitor (HDACs)
Other Names:
A selective humanized monoclonal antibody (mAb)
Other Names:
|
Experimental: Ph 2 NSCLC pre-treated PD-1/LD-L1
Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
|
An orally available histone deacetylases inhibitor (HDACs)
Other Names:
A selective humanized monoclonal antibody (mAb)
Other Names:
|
Experimental: Ph 2 Melanoma pre-treated PD-1/PD-L1
Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
|
An orally available histone deacetylases inhibitor (HDACs)
Other Names:
A selective humanized monoclonal antibody (mAb)
Other Names:
|
Experimental: Ph 2 Mismatch Repair-Proficient CRC
Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody
|
An orally available histone deacetylases inhibitor (HDACs)
Other Names:
A selective humanized monoclonal antibody (mAb)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants taking 3mg entinostat weekly with Adverse Events as a Measure of Safety and Tolerability
Time Frame: In approximately 3-4 months after 3-6 patients have enrolled and been on study for 1 cycle
|
Ph 1 Dose Escalation - All patients within each dose escalation cohort are to complete C1, have safety assessments performed through C2D1, and be assessed for DLT before enrollment of the next cohort may commence.
|
In approximately 3-4 months after 3-6 patients have enrolled and been on study for 1 cycle
|
Number of Participants taking 5mg entinostat weekly with Adverse Events as a Measure of Safety and Tolerability
Time Frame: In approximately 6-8 months after 3-6 patients have enrolled and been on study for 1 cycle
|
Ph 1 Dose Escalation - All patients within each dose escalation cohort are to complete C1, have safety assessments performed through C2D1, and be assessed for DLT before enrollment of the next cohort may commence.
|
In approximately 6-8 months after 3-6 patients have enrolled and been on study for 1 cycle
|
Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 1 Stage 1 (NSCLC)
Time Frame: In approximately 1 year
|
- Cohort 1 Stage 1: If enough patients achieve an objective response (CR or PR), enrollment will continue into the second stage.
|
In approximately 1 year
|
Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 2 Stage 1 (NSCLC pre-treated)
Time Frame: In approximately 1 year
|
- Cohort 2 Stage 1: If enough patients achieve an objective response, then enrollment will continue into the second stage.
|
In approximately 1 year
|
Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 1 (Melanoma pre-treated)
Time Frame: In approximately 1 year
|
- Cohort 3 Stage 1: If enough patients achieve an objective response, then enrollment will continue into the second stage.
|
In approximately 1 year
|
Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 1 Stage 2 (NSCLC)
Time Frame: In approximately 2 years
|
Cohort 1 Stage 2: If enough patients achieve a CR or PR than the true ORR for the combination therapy.
|
In approximately 2 years
|
Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 2 Stage 2 (NSCLC pre-treated)
Time Frame: In approximately 2 years
|
- Cohort 2 Stage 2: IIf enough patients achieve a CR or PR than the true ORR for the combination therapy.
|
In approximately 2 years
|
Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 2 (Melanoma pre-treated)
Time Frame: In approximately 2 years
|
Measured by Overall Response Rate using irRECIST. - Cohort 3 Stage 2: If enough patients achieve a CR or PR than the true ORR for the combination therapy. |
In approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Benefit Rate (CBR)
Time Frame: At 6 months of treatment for each of the 3 Dose Escalation (Ph 2 cohorts) as applicable
|
CBR is Complete Response + Partial Response + Stable Disease for each patient after 6 months of study treatment
|
At 6 months of treatment for each of the 3 Dose Escalation (Ph 2 cohorts) as applicable
|
Progression-free survival (PFS) @ 6mo
Time Frame: At 6 months of treatment for each of the 3 Dose Escalation (Ph 2 cohorts) as applicable
|
PFS status in each patient after 6 months of study treatment.
PFS is defined as the number of months from the date of the first dose of study drug to the earliest of documented PD or death due to any cause without prior progression.
|
At 6 months of treatment for each of the 3 Dose Escalation (Ph 2 cohorts) as applicable
|
Progression-free survival (PFS)
Time Frame: In approximately 3 years
|
PFS status in each patient.
PFS is defined as the number of months from the date of the first dose of study drug to the earliest of documented PD or death due to any cause without prior progression.
|
In approximately 3 years
|
Overall survival (OS)
Time Frame: In approximately 3 years
|
OS status in each patient.
OS is defined as the number of months from the first dose of study drug to the date of death due to any cause.
|
In approximately 3 years
|
Duration of Response (DOR)
Time Frame: In approximately 3 years
|
DOR will be calculated for patients who achieve a CR or PR and is defined as the number of months from the start date of the response (and subsequently confirmed) to the first date that recurrent disease or PD is documented.
|
In approximately 3 years
|
Time to Response (TTR)
Time Frame: In approximately 3 years
|
TTR status in each patient.
|
In approximately 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Passi A Janne, MD, PhD, Dana-Farber Cancer Institute
Publications and helpful links
General Publications
- Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10. doi: 10.1016/0197-2456(89)90015-9.
- Hellmann MD, Janne PA, Opyrchal M, Hafez N, Raez LE, Gabrilovich DI, Wang F, Trepel JB, Lee MJ, Yuno A, Lee S, Brouwer S, Sankoh S, Wang L, Tamang D, Schmidt EV, Meyers ML, Ramalingam SS, Shum E, Ordentlich P. Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. Clin Cancer Res. 2021 Feb 15;27(4):1019-1028. doi: 10.1158/1078-0432.CCR-20-3305. Epub 2020 Nov 17.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neuroendocrine Tumors
- Nevi and Melanomas
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Histone Deacetylase Inhibitors
- Pembrolizumab
- Entinostat
Other Study ID Numbers
- SNDX-275-0601
- KN 142 (Other Identifier: Merck & Co.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on entinostat
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative DiseasesUnited States
-
Hetty CarrawayActive, not recruitingAcute Myeloid LeukemiaUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)Completed
-
University Hospital HeidelbergGerman Cancer Research CenterRecruitingSolid Tumor | CNS TumorFrance, Germany, Australia, Austria, Sweden, Netherlands, Switzerland
-
Abramson Cancer Center at Penn MedicineCompletedColorectal CancerUnited States
-
Syndax PharmaceuticalsPfizer; Merck KGaA, Darmstadt, GermanyCompletedStudy of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian CancerFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal CancerUnited States
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaSyndax PharmaceuticalsWithdrawn
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Untreated Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaUnited States